[go: up one dir, main page]

DK1604679T3 - Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte - Google Patents

Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte

Info

Publication number
DK1604679T3
DK1604679T3 DK05006623.2T DK05006623T DK1604679T3 DK 1604679 T3 DK1604679 T3 DK 1604679T3 DK 05006623 T DK05006623 T DK 05006623T DK 1604679 T3 DK1604679 T3 DK 1604679T3
Authority
DK
Denmark
Prior art keywords
treatment
botulinum toxin
visceral pain
visceral
pain
Prior art date
Application number
DK05006623.2T
Other languages
English (en)
Inventor
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24196890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1604679(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1604679T3 publication Critical patent/DK1604679T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK05006623.2T 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte DK1604679T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/550,371 US6464986B1 (en) 2000-04-14 2000-04-14 Method for treating pain by peripheral administration of a neurotoxin
EP01924939A EP1272207B1 (en) 2000-04-14 2001-04-11 Use of a botulinum toxin for the manufacture of a medicament for peripheral administration for treating pain non associated to muscle spasm or headache

Publications (1)

Publication Number Publication Date
DK1604679T3 true DK1604679T3 (da) 2010-10-25

Family

ID=24196890

Family Applications (6)

Application Number Title Priority Date Filing Date
DK05006623.2T DK1604679T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK01924939T DK1272207T3 (da) 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK01924939T DK1272207T3 (da) 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte

Country Status (19)

Country Link
US (14) US6464986B1 (da)
EP (7) EP1550456B1 (da)
JP (1) JP4037652B2 (da)
KR (1) KR20030009431A (da)
CN (1) CN1188165C (da)
AR (1) AR030209A1 (da)
AT (6) ATE456375T1 (da)
AU (2) AU2001251546B9 (da)
BR (1) BR0110030A (da)
CA (3) CA2485920A1 (da)
CY (2) CY1108065T1 (da)
DE (6) DE60143061D1 (da)
DK (6) DK1604679T3 (da)
ES (7) ES2394314T3 (da)
MX (1) MXPA02009932A (da)
NZ (1) NZ521535A (da)
PT (2) PT1604680E (da)
TW (1) TWI282282B (da)
WO (1) WO2001078760A2 (da)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
CN102349914B (zh) * 2001-11-15 2015-01-28 微观藻类公司 包含3,4-丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7964644B2 (en) * 2002-07-19 2011-06-21 Mestex Ag Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means
BR0315319A (pt) * 2002-10-15 2005-08-16 Allergan Inc Terapias e procedimentos dentais com toxina botulìnica
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US7335367B2 (en) * 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
KR20050109969A (ko) * 2003-03-06 2005-11-22 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof
MXPA06012960A (es) * 2004-05-07 2007-06-12 Phytotox Ltd Administracion transdermal de ficotoxinas.
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1784420B1 (en) 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP1802339B1 (en) 2004-09-23 2011-09-21 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
JP4913074B2 (ja) 2005-03-03 2012-04-11 アラーガン、インコーポレイテッド 動物由来産物不含方法およびボツリヌス毒素を精製するための方法
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
EP1920248B1 (en) 2005-04-05 2010-09-29 Allergan, Inc. Clostridial toxin activity assays
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CA2611936C (en) * 2005-06-14 2017-01-03 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
AU2006346369B2 (en) 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
AU2007329579A1 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
BRPI0719732A2 (pt) * 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
ES2520765T3 (es) * 2007-02-15 2014-11-11 Allergan, Inc. Uso de toxina botulínica para el tratamiento de hiperhidrosis
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
US20100034854A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 KD)
US20100034853A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
AU2010221435B2 (en) 2009-03-06 2014-06-19 Allergan, Inc. Clostridial toxin to improve ejaculate
WO2011038015A1 (en) 2009-09-24 2011-03-31 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
EP3246035A1 (en) 2010-01-26 2017-11-22 Michael A. Evans Devices and agents for denervation
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
WO2012103415A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
EP2729163A1 (en) 2011-07-08 2014-05-14 Allergan, Inc. Method for treatment of autonomic nervous system disorders
KR20140054055A (ko) 2011-07-14 2014-05-08 알러간, 인코포레이티드 성행위와 관련된 실금의 치료방법
CN103702681A (zh) 2011-07-20 2014-04-02 阿勒根公司 用于治疗脂肪沉积的方法
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
WO2013153191A1 (en) 2012-04-13 2013-10-17 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (ii)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
EP2976060B1 (en) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
AU2015315571A1 (en) * 2014-09-12 2017-04-27 Allergan, Inc. Methods for treating osteoarthritis pain
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
HK1252915A1 (zh) * 2015-10-01 2019-06-06 戈勒尼股份有限公司 氯離子通道的靶向表達及其使用方法
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
CN110913868A (zh) 2017-05-24 2020-03-24 Atgc 股份有限公司 用于治疗足痛疾病的包括肉毒杆菌毒素和透明质酸的药物组合物以及使用其治疗足痛疾病的方法
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
CN111465352B (zh) 2018-02-26 2024-04-12 益普生生物制药有限公司 使用超声波引导非细胞毒性蛋白酶的注射
JP2021525251A (ja) 2018-05-21 2021-09-24 イプセン バイオファーム リミテッドＩｐｓｅｎ Ｂｉｏｐｈａｒｍ Ｌｉｍｉｔｅｄ 骨癌誘発性アロディニアの抑制
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693207B1 (fr) * 1992-07-03 1994-09-30 Orsan Souche de levure permettant la co-expression d'une activité mono-oxygénase de cytochrome P450 hétérologue et d'une NADPH-cytochrome P450-réductase endogène ou hétérologue et son utilisation à des fins de bioconversion.
EP0679090A1 (en) 1993-01-15 1995-11-02 Interactive Biologics Associates Method for treating myofascial pain syndrome
US5592212A (en) * 1993-04-16 1997-01-07 News Datacom Ltd. Methods and systems for non-program applications for subscriber television
DE69435149D1 (de) * 1993-12-28 2008-11-20 Allergan Inc Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
WO1995030431A1 (en) 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JPH08306853A (ja) * 1995-05-09 1996-11-22 Fujitsu Ltd 半導体装置及びその製造方法及びリードフレームの製造方法
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
EP1763315A4 (en) 2004-07-07 2009-03-04 Obstecare Inc METHOD FOR MONITORING BIRTH PROCESSES

Also Published As

Publication number Publication date
US7172763B2 (en) 2007-02-06
EP1576963A2 (en) 2005-09-21
ES2347256T3 (es) 2010-10-27
DE60142590D1 (de) 2010-08-26
JP2003531127A (ja) 2003-10-21
US7361358B2 (en) 2008-04-22
EP1272207B1 (en) 2007-06-13
US7288260B2 (en) 2007-10-30
US7374769B2 (en) 2008-05-20
CA2485920A1 (en) 2001-10-25
US20020176872A1 (en) 2002-11-28
US20040018213A1 (en) 2004-01-29
DK1604678T3 (da) 2010-10-18
US20050152925A1 (en) 2005-07-14
CA2406367A1 (en) 2001-10-25
US7211262B2 (en) 2007-05-01
EP1604680B1 (en) 2010-01-27
US7276245B2 (en) 2007-10-02
NZ521535A (en) 2004-09-24
AU5154601A (en) 2001-10-30
US6869610B2 (en) 2005-03-22
DE60141230D1 (de) 2010-03-18
US7294339B2 (en) 2007-11-13
EP1604678B1 (en) 2010-07-14
PT1604680E (pt) 2010-02-11
DE60128899T2 (de) 2008-02-21
US20080138364A1 (en) 2008-06-12
EP1272207A2 (en) 2003-01-08
DE60142712D1 (de) 2010-09-09
DK1272207T3 (da) 2007-09-10
EP1604680A1 (en) 2005-12-14
CN1188165C (zh) 2005-02-09
DE60143061D1 (de) 2010-10-21
DK1576963T3 (da) 2011-02-21
ES2347792T3 (es) 2010-11-04
DE60128899D1 (de) 2007-07-26
US7291344B2 (en) 2007-11-06
ES2287117T3 (es) 2007-12-16
CA2406367C (en) 2008-01-29
US20070014816A1 (en) 2007-01-18
WO2001078760A3 (en) 2002-03-21
ES2338238T3 (es) 2010-05-05
ES2353878T3 (es) 2011-03-07
EP1550456A3 (en) 2005-12-07
US20060039917A1 (en) 2006-02-23
CA2485919A1 (en) 2001-10-25
ATE364393T1 (de) 2007-07-15
ATE480253T1 (de) 2010-09-15
WO2001078760A2 (en) 2001-10-25
ATE475427T1 (de) 2010-08-15
EP1550456B1 (en) 2012-09-26
EP1576963B1 (en) 2010-11-24
ATE456375T1 (de) 2010-02-15
US6464986B1 (en) 2002-10-15
US20040018212A1 (en) 2004-01-29
US20040018214A1 (en) 2004-01-29
DE60143549D1 (de) 2011-01-05
ATE473753T1 (de) 2010-07-15
AU2001251546B9 (en) 2004-12-02
CY1109972T1 (el) 2014-09-10
MXPA02009932A (es) 2004-08-19
EP1604679A1 (en) 2005-12-14
EP1604681B1 (en) 2010-09-08
ES2394314T3 (es) 2013-01-30
ES2349782T3 (es) 2011-01-11
DK1604680T3 (da) 2010-05-10
US20060275326A1 (en) 2006-12-07
EP1604681A1 (en) 2005-12-14
TWI282282B (en) 2007-06-11
US20050058666A1 (en) 2005-03-17
US7067137B2 (en) 2006-06-27
CY1108065T1 (el) 2014-02-12
EP1604679B1 (en) 2010-07-28
JP4037652B2 (ja) 2008-01-23
US7468189B2 (en) 2008-12-23
AR030209A1 (es) 2003-08-13
BR0110030A (pt) 2003-06-03
EP1604678A1 (en) 2005-12-14
PT1272207E (pt) 2007-06-29
EP1550456A2 (en) 2005-07-06
US20040028706A1 (en) 2004-02-12
US20060039916A1 (en) 2006-02-23
KR20030009431A (ko) 2003-01-29
DK1604681T3 (da) 2010-11-29
EP1576963A3 (en) 2005-12-07
ATE489102T1 (de) 2010-12-15
AU2001251546B2 (en) 2004-07-01
US20060275325A1 (en) 2006-12-07
CN1436085A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
DK1604679T3 (da) Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
ATE473944T1 (de) Mittel zur wasserbehandlung
DE60017241D1 (de) Unterwasserbehandlungsanordnung und -verfahren
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DK1267650T3 (da) Tobakbehandling
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
BR0205514B1 (pt) processos de tratamento de cabelo
NO20032122D0 (no) Forbedret behandling
DE60223576D1 (de) Hautbehandlungszusammensetzung
PT1248608E (pt) Substancias para usar no tratamento de psoriase
PT1326628E (pt) Mutantes de quimioquinas no tratamento de esclerose multipla
DE60102459D1 (de) Lockenwickler
DE60009451D1 (de) Massagegerät
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
DE60222664D1 (de) Hautbehandlungsmittel
DE60023003D1 (de) Haarbehandlungsmittel
BR0114005B1 (pt) composição para tratamento de tecido
DE60125241D1 (de) Wärmebehandlungseinrichtung
FIU990415U0 (fi) Saunasuodatin
FI20030276A7 (fi) Palovammojen hoitaminen
DE50109641D1 (de) Textilbehandlungsmittel
FI20002308A7 (fi) Saunan kiuas
FI20001787L (fi) Höyrykäsittely